Eligibility criteria (postmenopausal, Stage II to III BC)
90 Patients

- Placebo
  - N = 29
- Anastrozole 1 mg/day
  - N = 25
- Tamoxifen 20 mg/day
  - N = 24

Randomization

- Surgery (after 26 days)

12 protocol violations:
- 8 subjects did not take tablets correctly
- 3 subjects did not proceed to surgery in time
- 1 hormone analysis

Biopsy before randomization
Tumor markers: ER-α, ER-β, Ki-67

Tumor markers: ER-α, ER-β, Ki-67